Amgen’s weight-loss drug MariTide fails to meet expectations
Amgen, a leading biotechnology company, announced today that its investigational weight-loss drug, MariTide (maridebart cafraglutide), did not meet its primary endpoint in a Phase 2 clinical trial. The news sent … Read More